For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
According to our LPI (LP Information) latest study, the global Celecoxib market size was valued at US$ 1243.6 million in 2023. With growing demand in downstream market, the Celecoxib is forecast to a readjusted size of US$ 2232 million by 2030 with a CAGR of 8.7% during review period.
The research report highlights the growth potential of the global Celecoxib market. Celecoxib are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Celecoxib. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Celecoxib market.
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Key Features:
The report on Celecoxib market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Celecoxib market. It may include historical data, market Segmentation by Type (e.g., 50mg, 100mg), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Celecoxib market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Celecoxib market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Celecoxib industry. This include advancements in Celecoxib technology, Celecoxib new entrants, Celecoxib new investment, and other innovations that are shaping the future of Celecoxib.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Celecoxib market. It includes factors influencing customer ' purchasing decisions, preferences for Celecoxib product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Celecoxib market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Celecoxib market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Celecoxib market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Celecoxib industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Celecoxib market.
Market Segmentation:
Celecoxib market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- 50mg
- 100mg
- 200mg
- 400mg
Segmentation by application
- Rheumatoid arthritis
- osteoarthritis
- Acute pain
- Musculoskeletal pain
- Other diseases
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Pfizer Inc
- Teva
- Mylan
- Apotex
- Lupin
- Hengrui Medicine
Key Questions Addressed in this Report
What is the 10-year outlook for the global Celecoxib market?
What factors are driving Celecoxib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Celecoxib market opportunities vary by end market size?
How does Celecoxib break out type, application?